BioMicro Systems Inc., of Salt Lake City, elected director Stephen Blose as chairman.

Clinical Data Inc., of Newton, Mass., said its Vital Scientific NV unit appointed Herman Buis international sales manager.

DFB Branded Pharmaceuticals, of Fort Worth, Texas, hired Herbert Slade in the newly created position of chief medical officer and senior vice president of medical affairs. It also named Mike Bernstein vice president of regulatory affairs.

Enigma Diagnostics, of Porton Down, UK, appointed Lynn Busteed CEO. It also has appointed Biresh Roy chief financial officer and Mo Aslam program director.

Exelixis Inc., of South San Francisco, appointed Richard Buller to the newly created position of vice president, translational medicine.

Gene Logic Inc., of Gaithersburg, Md., promoted Thomas Barnes to senior vice president, discovery. It also elected David Urdal and Mark Gabrielson as directors.

GeneNews Ltd., of Toronto, appointed Ming Xu as director, product development. In addition, interim chief financial officer Colin West was appointed vice president, finance and CFO.

GenVec Inc., of Gaithersburg, Md., appointed Marc Schneebaum to its board.

IDM Pharma Inc., of Irvine, Calif., said Edward Penhoet joined its board.

Inogen Inc., of Santa Barbara, Calif., said Scott Greer joined the company's board.

Invitrogen Corp., of Carlsbad, Calif., appointed Farnaz Khadem director of corporate communications.

Iroko Pharmaceuticals LLC, of Philadelphia, appointed John Vavricka president and CEO. It also appointed Fred Krieger chief financial officer, Rohit Mehta vice president of corporate development, Joseph Crea executive director manufacturing and Hanna Zyruk director of regulatory affairs.

IsoTis Inc., of Irvine, Calif., appointed James Abraham senior vice president of sales.

Kuros AG, of Zurich, Switzerland, appointed Fritz Kunz chairman and Edward Currie chief operating officer.

Molecular Insight Pharmaceuticals Inc., of Cambridge, Mass., appointed Brian Abeysekera to the new position of vice president, manufacturing.

New Leaf Venture Partners, of New York, appointed Milton McColl as a venture partner, based in the Menlo Park, Calif., office.

Novagali Pharma, of Evry France, appointed Philippe Garcia chief financial officer.

Osteotech Inc., of Eatontown, N.J., appointed James Shannon to its board.

Oxford Genome Sciences Ltd., of Oxford, UK, hired Benjamin Reed as business development director of its Biomarker Services Division and David Bell as head of mass spectrometry operations. It also named Mike Gresser to head its U.S.-based preclinical operations, while David Fitzpatrick will lead the preclinical development team and Beatrice Perotti will lead preclinical development programs.

Panacos Pharmaceuticals Inc., of Watertown, Mass., appointed Robert Savage to its board.

Pipex Pharmaceuticals Inc., of Ann Arbor, Mich., appointed Kay Stremler vice president of manufacturing.

Polaris Venture Partners, of Waltham, Mass., named Amir Nashat a general partner.

Senesco Technologies Inc., of New Brunswick, N.J., added James Mier to its scientific advisory board.

Speedel Holding, of Basel, Switzerland, named Michael Merz head of clinical research and development.

Sunesis Pharmaceuticals Inc., of South San Francisco, appointed Valerie Pierce senior vice president, general counsel and corporate secretary.

Synta Pharmaceuticals Corp., of Lexington, Mass., hired Anthony Williams as vice president of clinical research and Mary Drummond as director of commercial development for oncology.

TargeGen Inc., of San Diego, appointed Martin Friedlander to its scientific advisory board.

The Medicines Co., of Parsippany, N.J., appointed Hiroaki Shigeta to its board.

Transgenomic Inc., of Omaha, Neb., appointed Frank Witney to its board.

Vasogen Inc., of Toronto, said Chief Operating Officer Christopher Waddick also will assume the title of chief financial officer; and Eldon Smith, vice president, scientific affairs and director, will assume all responsibilities of the position of chief medical officer and head of cardiovascular development.

VentiRx Pharmaceuticals Inc., of San Diego, appointed Kent Snyder to its board.

Vion Pharmaceuticals Inc., of New Haven, Conn., hired James Tanguay as vice president, chemistry, manufacturing and control.

No Comments